Myovant Sciences Ltd.
(NYSE : MYOV)

( )
MYOV PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
0.67%345.221.2%$624.02m
GILDGilead Sciences, Inc.
-3.53%72.920.9%$510.71m
CELGCelgene Corporation
0.24%90.371.2%$496.41m
AMGNAmgen Inc.
0.50%197.421.2%$485.34m
ILMNIllumina, Inc.
-0.34%325.883.5%$373.70m
REGNRegeneron Pharmaceuticals, Inc.
0.67%374.262.6%$315.78m
VRTXVertex Pharmaceuticals Incorporated
0.64%176.081.9%$209.08m
ALXNAlexion Pharmaceuticals, Inc.
-1.09%116.002.0%$186.59m
AAgilent Technologies, Inc.
-1.28%64.661.5%$159.27m
SRPTSarepta Therapeutics, Inc.
0.52%130.2516.6%$142.46m
NKTRNektar Therapeutics
0.13%60.035.6%$126.29m
BLUEBluebird Bio, Inc.
1.15%158.0014.6%$121.57m
EXASExact Sciences Corporation
0.33%48.8425.3%$118.82m
BMRNBioMarin Pharmaceutical Inc.
0.69%101.014.4%$118.74m
INCYIncyte Corporation
1.40%68.802.5%$111.73m

Company Profile

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.